Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Tuberculosis
Would you consider adding azithromycin to standard antituberculosis treatment to reduce inflammation and tissue damage in patients with pulmonary tuberculosis?
Dekkers BG, et al., PMID 39932906
Related Questions
What is the interpretation of an IGRA with positive TB wells and negative nil and negative mitogen wells?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
What are your top takeaways from ID Week 2024?
What is your preferred method for latent tuberculosis screening prior to outpatient hemodialysis initiation for a patient with new dialysis requirements?
What is the interpretation of two IGRAs with negative mitogen wells, in the absence of immunosuppression?
Do you switch to an alternative agent for C difficile colitis for a patient with suspected infection and positive testing who continues to have >3 watery bowel movements daily despite multiple days of oral vancomycin treatment?
Do you have any concerns about using long-acting cabotegravir/rilpivirine in obese patients with HIV?
How long do you treat Staphylococcus aureus pyomyositis with antibiotics?
Do you favor a certain NRTI to pair with dolutegravir and lamivudine in persons with HIV to minimize the risk of resistance to dolutegravir?
How do you consider sending fungal studies in a patient with pneumonia?
